Answers are grounded in this paper and cite their sources.
Interlaboratory variability affects clinical decisions in myositis autoantibody testing, suggesting urgent need for harmonization.
We have shown there is considerable variation in how myositis antibody testing is undertaken and the results obtained for key autoantibody specificities, which may impact on clinical decision-making. Dialogue between manufacturers, diagnostic laboratories and clinicians remains crucial and steps towards harmonisation between laboratories is urgently needed.
No takes yet. Share an insight, caveat, or question.
Harvey et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: